Zynerbia Pharmaceuticals Inc. (NASDAQ: ZYNE) has appointed Albert Parker as its Chief Legal Officer and Corporate Sectary to replace Suzanne Hanlon, who is retiring at the...
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) has given program updates for autism spectrum disorder(ASD), Fragile X syndrome (FXS), developmental and epileptic encephalopathies (DEE), and 22q11.2 deletion syndrome...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reports a net loss of $9.6 million in Q4 2020. Its R&D expenses and G&A (General and Administrative) expenses are $5.6 million...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has reported a net loss of $10.7 million in Q4 2019. Its cash and cash equivalents in 2019 are $70.1 million. According...
